Chiglitazar

The theme of Chiglitazar is one that has captured the attention of scientists, researchers and enthusiasts alike. Its impact has been felt in various areas, from science and technology to politics and popular culture. Over the years, it has become a topic of debate and discussion, generating conflicting opinions and controversial theories. In this article, we will take a deep look at Chiglitazar and explore its implications in today's world. From its origins to its current impact, we will delve into the fascinating world of Chiglitazar and discover how it has shaped our perception and understanding of the world around us.

Chiglitazar
Clinical data
Trade namesBilessglu
Other namesCarfloglitazar
Legal status
Legal status
  • Rx in China
Identifiers
  • (2S)-3--2-propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H29FN2O4
Molar mass572.636 g·mol−1
3D model (JSmol)
  • C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C(C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
  • InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
  • Key:QNLWMPLUWMWDMQ-YTTGMZPUSA-N

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.[2]

References

  1. ^ Ji L, Song W, Fang H, Li W, Geng J, Wang Y, et al. (August 2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi:10.1016/j.scib.2021.03.019. PMID 36654286. S2CID 233650336.
  2. ^ Deeks ED (January 2022). "Chiglitazar: First Approval". Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.